NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

Neuropace Inc NPCE:

• NEUROPACE INC: REAFFIRMS ITS PREVIOUSLY ISSUED FULL-YEAR 2025 FINANCIAL GUIDANCE

• NEUROPACE INC - COMPLETES PRIMARY ENDPOINT ANALYSIS FOR IDIOPATHIC GENERALIZED EPILEPSY STUDY

• NEUROPACE INC - STUDY MEETS 12-WEEK POST-IMPLANT SAFETY ENDPOINT

• NEUROPACE INC - PRELIMINARY DATA SHOWS FAVORABLE SEIZURE REDUCTION RATES FOR RNS SYSTEM

• NEUROPACE - PRIMARY EFFECTIVENESS ENDPOINT NOT STATISTICALLY SIGNIFICANT IN OVERALL POPULATION